论文部分内容阅读
作者用左旋咪唑(LMZ)试用于30例眼角膜疱疹病毒感染的病人。男19例、女11例,年龄5～60岁。其中17例有既往史,13例为初发者。按临床标准确诊病例,并作细胞免疫功能(包括E 花结形成细胞数—ERFC,T 细胞数/mm~3和皮试)。所有病例均用碘苷、阿托品作局部治疗。随机选择15例为不给药对照组,15例治疗组,LMZ2.5mg/kg/天,每周连续服药3天,共3个月,记录治疗前后的复发次数和复发间隔。结果表明,对照组急性发作的平均持续时间为35.7天,治疗组为25.1天,10例病人的基质结构和角膜透明度有所改善。试验前,对照组7/15病人有复发史,大约6个月
The authors tested levamisole (LMZ) in 30 patients with corneal herpesvirus infection. 19 males and 11 females, aged 5 to 60 years old. Of these, 17 had prior history and 13 had first episodes. According to clinical diagnosis of cases, and for cellular immune function (including the number of E-flow forming cells-ERFC, T cells / mm ~ 3 and skin test). All cases were treated with iodine, atropine for local treatment. 15 cases were randomly selected as the control group, 15 cases of treatment group, LMZ2.5mg / kg / day, taking 3 consecutive days a week for 3 months, record the number of recurrences before and after treatment and recurrence interval. The results showed that the mean duration of acute exacerbation in the control group was 35.7 days compared with 25.1 days in the treatment group, and the matrix structure and corneal transparency were improved in 10 patients. Before the trial, 7/15 patients in the control group had a relapse history of about 6 months